FLAM
First Light Asset Management Portfolio holdings
AUM
$771M
This Quarter Return
+10.54%
1 Year Return
+33.17%
3 Year Return
+208.13%
5 Year Return
+426.73%
10 Year Return
+3,318.8%
AUM
$1.51B
AUM Growth
+$1.51B
(+12%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
8.7%
Top 10 Holdings %
Top 10 Hldgs %
43.35%
Holding
93
New
19
Increased
39
Reduced
13
Closed
16
Top Buys
| 1 |
CUTR
Cutera, Inc.
CUTR
|
$37.4M |
| 2 |
Aldeyra Therapeutics
ALDX
|
$31.2M |
| 3 |
Sutro Biopharma
STRO
|
$28M |
| 4 |
NeoGenomics
NEO
|
$23.4M |
| 5 |
Tandem Diabetes Care
TNDM
|
$22.8M |
Top Sells
| 1 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
$86.4M |
| 2 |
CareDx
CDNA
|
$39.1M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$26.6M |
| 4 |
Halozyme
HALO
|
$23.4M |
| 5 |
Glaukos
GKOS
|
$12.2M |
Sector Composition
| 1 | Healthcare | 84.27% |
| 2 | Communication Services | 4.55% |
| 3 | Energy | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPNE
1
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $94.4M | 6.26% | 5,426,241 +74,748 | +1% | +$1.3M |
|
|
2
Halozyme
HALO
$8.56B
| $83.9M | 5.56% | 2,011,350 -560,542 | -22% | -$23.4M |
|
|
3
CareDx
CDNA
$727M
| $82.6M | 5.47% | 1,212,677 -574,960 | -32% | -$39.1M |
|
4
Prothena Corp
PRTA
$441M
| $73.7M | 4.89% | 2,935,707 +879,254 | +43% | +$22.1M |
|
|
MODN
5
DELISTED
MODEL N, INC.
MODN
| $68.7M | 4.55% | 1,949,762 +639,749 | +49% | +$22.5M |
|
6
AtriCure
ATRC
$1.84B
| $54.3M | 3.6% | 828,002 +18,692 | +2% | +$1.22M |
|
7
Axogen
AXGN
$743M
| $51.8M | 3.44% | 2,557,412 +418,278 | +20% | +$8.47M |
|
8
Omnicell
OMCL
$1.5B
| $49.2M | 3.26% | 379,075 -61,171 | -14% | -$7.94M |
|
|
9
NeoGenomics
NEO
$1.13B
| $48.4M | 3.21% | 1,003,216 +486,125 | +94% | +$23.4M |
|
|
10
Sutro Biopharma
STRO
$72.7M
| $46.9M | 3.11% | 2,058,447 +1,231,346 | +149% | +$28M |
|
11
Health Catalyst
HCAT
$239M
| $46.6M | 3.09% | 997,201 +25,304 | +3% | +$1.18M |
|
|
12
Tandem Diabetes Care
TNDM
$845M
| $46.3M | 3.07% | 525,129 +257,855 | +96% | +$22.8M |
|
|
13
Glaukos
GKOS
$5.5B
| $44.7M | 2.96% | 532,657 -145,650 | -21% | -$12.2M |
|
|
XENT
14
DELISTED
Intersect ENT, Inc
XENT
| $42.5M | 2.82% | 2,036,645 +813,684 | +67% | +$17M |
|
15
Teva Pharmaceuticals
TEVA
$21.1B
| $42.4M | 2.81% | 3,674,104 +282,692 | +8% | +$3.26M |
|
16
Krystal Biotech
KRYS
$4.27B
| $37.9M | 2.51% | 491,511 -229 | -0% | -$17.6K |
|
|
CUTR
17
DELISTED
Cutera, Inc.
CUTR
| $37.4M | 2.48% | +1,244,117 | New | +$37.4M |
|
18
Arrowhead Research
ARWR
$3.05B
| $35.6M | 2.36% | 536,836 -167,613 | -24% | -$11.1M |
|
19
Insmed
INSM
$28.8B
| $32.4M | 2.15% | 950,953 -120,266 | -11% | -$4.1M |
|
|
20
Aldeyra Therapeutics
ALDX
$351M
| $31.2M | 2.07% | +2,624,001 | New | +$31.2M |
|
|
KRTX
21
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $31.1M | 2.06% | 258,500 +121,100 | +88% | +$14.6M |
|
22
OptimizeRx
OPRX
$335M
| $29M | 1.92% | 594,199 -91,501 | -13% | -$4.46M |
|
23
Y-mAbs Therapeutics
YMAB
$388M
| $28.6M | 1.89% | 944,253 +308,601 | +49% | +$9.33M |
|
24
Ultragenyx Pharmaceutical
RARE
$2.89B
| $24.8M | 1.64% | 217,459 +3,572 | +2% | +$407K |
|
25
Genmab
GMAB
$15.3B
| $24.2M | 1.6% | 737,261 +100,177 | +16% | +$3.29M |
|